Avadel Completes Patient Enrollment in REVITALYZ Trial, Data Expected Q2 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 18 2025
0mins
Should l Buy AVDL?
Source: Newsfilter
- Trial Enrollment Completion: Avadel Pharmaceuticals announced the completion of patient enrollment in the REVITALYZ trial, which evaluates LUMRYZ as a potential treatment for idiopathic hypersomnia, with data expected in Q2 2026, marking a significant advancement for the company in this area.
- Clinical Trial Design: REVITALYZ is a double-blind, placebo-controlled multicenter Phase 3 trial designed to assess the efficacy and safety of LUMRYZ, particularly its effects on reducing daytime sleepiness, which, if approved by the FDA, will provide new treatment options for patients.
- Market Demand: Idiopathic hypersomnia is a serious sleep disorder affecting approximately 40,000 diagnosed patients in the U.S., and the development of LUMRYZ aims to meet this unmet market need, potentially enhancing Avadel's market position in the biopharmaceutical sector if successfully launched.
- Strategic Implications: As the first once-at-bedtime sodium oxybate medication, LUMRYZ has already achieved success in narcolepsy patients, and gaining approval for idiopathic hypersomnia would further solidify Avadel's image as an innovator in pharmaceuticals and drive long-term growth for the company.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AVDL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AVDL
Wall Street analysts forecast AVDL stock price to fall
10 Analyst Rating
0 Buy
10 Hold
0 Sell
Hold
Current: 21.640
Low
18.50
Averages
20.29
High
22.50
Current: 21.640
Low
18.50
Averages
20.29
High
22.50
About AVDL
Avadel Pharmaceuticals PLC is a biopharmaceutical company. The Company's product, LUMRYZ, is an extended-release formulation of sodium oxybate, indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the challenges patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME, and MEDUSA. Its MICROPUMP technology allows for the development of modified-release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified-release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Alkermes Acquires Avadel to Expand Product Portfolio
- Acquisition Completed: Alkermes has completed its acquisition of Avadel, adding the FDA-approved product LUMRYZ® to its portfolio, which is expected to be accretive in 2026, significantly enhancing the company's competitiveness in the sleep medicine market.
- Market Potential: LUMRYZ® targets over 50,000 eligible patients in the U.S., which is anticipated to drive Alkermes' revenue growth and further solidify its leadership position in the treatment of neurological disorders.
- Financial Arrangement: The acquisition cost approximately $775 million in cash and $1.525 billion in term loans, which Alkermes expects to pay down quickly with cash flows from the business, enhancing financial stability.
- Strategic Development: The acquisition will accelerate Alkermes' entry into the sleep medicine market and support its upcoming clinical development, particularly the planned phase 3 program for narcolepsy.
See More
State Street Increases Stake in Avadel Pharmaceuticals by 2.39%
- Stake Increase: State Street Global Advisors and affiliates increased their stake in Avadel Pharmaceuticals plc on January 16, 2026, holding 2,326,632 shares, which represents 2.39% of total shares, indicating confidence and investment intent in the company.
- Transaction Details: In this transaction, State Street purchased a total of 29,196 shares at a price of $21.48 each, reflecting optimism about Avadel's future growth potential, which may influence the overall market perception of the stock.
- Market Reaction: This stake increase could attract market attention towards Avadel Pharmaceuticals, especially if the stock price remains stable, prompting investors to reassess the company's value and prospects.
- Disclosure Compliance: In accordance with the Irish Takeover Panel regulations, State Street's trading information was disclosed on January 19, 2026, ensuring transparency and compliance, which further enhances market trust in its regulatory adherence.
See More
State Street Increases Stake in Avadel Pharmaceuticals by 2.36%
- Stake Increase: State Street Global Advisors and its affiliates increased their stake in Avadel Pharmaceuticals plc on January 15, 2026, holding 2,298,069 shares, which represents 2.36% of total shares, indicating confidence and a long-term investment strategy in the company.
- Transaction Price: The purchase price per share was $621.48, reflecting market recognition of Avadel, which may influence its stock price trajectory and increase investor interest in the company.
- Market Impact: State Street's stake increase could enhance Avadel's visibility among investors, attracting more institutional interest and potentially driving up its stock price, thereby boosting market confidence.
- Future Outlook: With State Street's increased stake, Avadel Pharmaceuticals may gain more market support and resources in the future, further driving its business development and market expansion.
See More
State Street Increases Stake in Avadel Pharmaceuticals, Holding Reaches 2.36%
- Increased Stake: State Street Global Advisors and its affiliates increased their stake in Avadel Pharmaceuticals plc on January 14, 2026, holding 2,298,063 shares, which represents 2.36% of total shares, indicating ongoing confidence in the company.
- Transaction Details: In this transaction, State Street purchased 6,500 shares at $21.50 each while simultaneously selling the same number of shares, reflecting an active trading strategy in the market.
- Market Impact Analysis: This increase in stake may positively influence Avadel's stock price, enhancing market confidence in its future growth potential, particularly in the context of its product line expansion and strategic adjustments.
- Transparency and Compliance: The disclosure of State Street's transactions complies with the regulations set by the Irish Takeover Panel, further enhancing market trust in its compliance practices.
See More
Avadel Pharmaceuticals Shareholders Approve Alkermes Buyout
- Acquisition Approval: Shareholders of Avadel Pharmaceuticals have approved the buyout proposal by Alkermes, marking a significant step in the company's strategic restructuring, which is expected to enhance Alkermes' market position in the biopharmaceutical sector.
- Shareholder Support: The vote reflects broad shareholder support for the acquisition, indicating confidence in the future integration benefits and synergies, which may enhance both companies' capabilities in research and marketing.
- Market Reaction: Following the acquisition announcement, the market showed a positive response towards the stocks of Avadel and Alkermes, indicating optimistic expectations from investors, which could drive stock prices higher.
- Strategic Integration: This acquisition will enable Alkermes to expand its product portfolio and leverage Avadel's technology platform, further solidifying its competitive advantage in therapeutic areas and laying the groundwork for future growth.
See More
State Street Increases Stake in Avadel Pharmaceuticals by 2.36%
- Stake Increase: On January 8, 2026, State Street Global Advisors and its affiliates increased their stake in Avadel Pharmaceuticals plc to 2,299,746 shares, representing 2.36% of total shares, indicating confidence in the company's prospects.
- Transaction Price: The purchase price for this stake was $21.48 per share, reflecting market recognition of Avadel's future growth potential, which may influence investor sentiment towards the stock.
- Market Impact: State Street's stake increase could enhance Avadel's market image, attracting more investor attention and potentially driving the stock price up in the short term, thereby strengthening its competitive position in the biopharmaceutical sector.
- Investment Strategy: This transaction indicates State Street's long-term investment strategy in Avadel, suggesting a possibility of further increasing their stake to capitalize on the company's potential growth opportunities in the pharmaceutical industry.
See More
Alkermes Acquires Avadel to Expand Product Portfolio
- Acquisition Completed: Alkermes has completed its acquisition of Avadel, adding the FDA-approved product LUMRYZ® to its portfolio, which is expected to be accretive in 2026, significantly enhancing the company's competitiveness in the sleep medicine market.
- Market Potential: LUMRYZ® targets over 50,000 eligible patients in the U.S., which is anticipated to drive Alkermes' revenue growth and further solidify its leadership position in the treatment of neurological disorders.
- Financial Arrangement: The acquisition cost approximately $775 million in cash and $1.525 billion in term loans, which Alkermes expects to pay down quickly with cash flows from the business, enhancing financial stability.
- Strategic Development: The acquisition will accelerate Alkermes' entry into the sleep medicine market and support its upcoming clinical development, particularly the planned phase 3 program for narcolepsy.
See More
State Street Increases Stake in Avadel Pharmaceuticals by 2.39%
- Stake Increase: State Street Global Advisors and affiliates increased their stake in Avadel Pharmaceuticals plc on January 16, 2026, holding 2,326,632 shares, which represents 2.39% of total shares, indicating confidence and investment intent in the company.
- Transaction Details: In this transaction, State Street purchased a total of 29,196 shares at a price of $21.48 each, reflecting optimism about Avadel's future growth potential, which may influence the overall market perception of the stock.
- Market Reaction: This stake increase could attract market attention towards Avadel Pharmaceuticals, especially if the stock price remains stable, prompting investors to reassess the company's value and prospects.
- Disclosure Compliance: In accordance with the Irish Takeover Panel regulations, State Street's trading information was disclosed on January 19, 2026, ensuring transparency and compliance, which further enhances market trust in its regulatory adherence.
See More
State Street Increases Stake in Avadel Pharmaceuticals by 2.36%
- Stake Increase: State Street Global Advisors and its affiliates increased their stake in Avadel Pharmaceuticals plc on January 15, 2026, holding 2,298,069 shares, which represents 2.36% of total shares, indicating confidence and a long-term investment strategy in the company.
- Transaction Price: The purchase price per share was $621.48, reflecting market recognition of Avadel, which may influence its stock price trajectory and increase investor interest in the company.
- Market Impact: State Street's stake increase could enhance Avadel's visibility among investors, attracting more institutional interest and potentially driving up its stock price, thereby boosting market confidence.
- Future Outlook: With State Street's increased stake, Avadel Pharmaceuticals may gain more market support and resources in the future, further driving its business development and market expansion.
See More
State Street Increases Stake in Avadel Pharmaceuticals, Holding Reaches 2.36%
- Increased Stake: State Street Global Advisors and its affiliates increased their stake in Avadel Pharmaceuticals plc on January 14, 2026, holding 2,298,063 shares, which represents 2.36% of total shares, indicating ongoing confidence in the company.
- Transaction Details: In this transaction, State Street purchased 6,500 shares at $21.50 each while simultaneously selling the same number of shares, reflecting an active trading strategy in the market.
- Market Impact Analysis: This increase in stake may positively influence Avadel's stock price, enhancing market confidence in its future growth potential, particularly in the context of its product line expansion and strategic adjustments.
- Transparency and Compliance: The disclosure of State Street's transactions complies with the regulations set by the Irish Takeover Panel, further enhancing market trust in its compliance practices.
See More
Avadel Pharmaceuticals Shareholders Approve Alkermes Buyout
- Acquisition Approval: Shareholders of Avadel Pharmaceuticals have approved the buyout proposal by Alkermes, marking a significant step in the company's strategic restructuring, which is expected to enhance Alkermes' market position in the biopharmaceutical sector.
- Shareholder Support: The vote reflects broad shareholder support for the acquisition, indicating confidence in the future integration benefits and synergies, which may enhance both companies' capabilities in research and marketing.
- Market Reaction: Following the acquisition announcement, the market showed a positive response towards the stocks of Avadel and Alkermes, indicating optimistic expectations from investors, which could drive stock prices higher.
- Strategic Integration: This acquisition will enable Alkermes to expand its product portfolio and leverage Avadel's technology platform, further solidifying its competitive advantage in therapeutic areas and laying the groundwork for future growth.
See More
State Street Increases Stake in Avadel Pharmaceuticals by 2.36%
- Stake Increase: On January 8, 2026, State Street Global Advisors and its affiliates increased their stake in Avadel Pharmaceuticals plc to 2,299,746 shares, representing 2.36% of total shares, indicating confidence in the company's prospects.
- Transaction Price: The purchase price for this stake was $21.48 per share, reflecting market recognition of Avadel's future growth potential, which may influence investor sentiment towards the stock.
- Market Impact: State Street's stake increase could enhance Avadel's market image, attracting more investor attention and potentially driving the stock price up in the short term, thereby strengthening its competitive position in the biopharmaceutical sector.
- Investment Strategy: This transaction indicates State Street's long-term investment strategy in Avadel, suggesting a possibility of further increasing their stake to capitalize on the company's potential growth opportunities in the pharmaceutical industry.
See More
